Neoadjuvant Immune-Checkpoint Blockade in Triple-Negative Breast Cancer: Current Evidence and Literature-Based Meta-Analysis of Randomized Trials.
immune check point inhibitor
meta-analysis
neoadjuvant therapy
triple-negative breast cancer
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
03 Sep 2020
03 Sep 2020
Historique:
received:
20
07
2020
revised:
26
08
2020
accepted:
28
08
2020
entrez:
9
9
2020
pubmed:
10
9
2020
medline:
10
9
2020
Statut:
epublish
Résumé
Chemotherapy based on the sequential use of anthracyclines and taxanes has long represented the most efficacious approach in the management of early-stage, triple-negative breast cancer, whose aggressive behavior is widely renowned. This standard chemotherapy backbone was subsequently enriched by the use of carboplatin, based on its association with increased pathologic complete response and efficacy in the metastatic setting. Following the results from the IMpassion130 trial, the recent approval of the immunotherapic agent atezolizumab in combination with chemotherapy as first-line treatment for programmed-death ligand 1-positive, unresectable locally advanced, or metastatic triple-negative breast cancer increasingly fueled the flourishing of trials of immune-checkpoint inhibitors in the early setting. In this work, we review the most recent inherent literature in light of key methodological issues and provide a quantitative summary of the results from phase II-III randomized trials of immunotherapic agents combined with chemotherapy in the setting of interest. Hints regarding future directions are also discussed.
Identifiants
pubmed: 32899209
pii: cancers12092497
doi: 10.3390/cancers12092497
pmc: PMC7565914
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Nat Rev Immunol. 2020 Jan;20(1):7-24
pubmed: 31467405
JAMA Oncol. 2020 May 1;6(5):676-684
pubmed: 32053137
Nat Med. 2018 Jul;24(7):986-993
pubmed: 29942092
Expert Opin Pharmacother. 2020 Apr;21(6):687-699
pubmed: 32052646
Nat Rev Clin Oncol. 2017 Jun;14(6):381-390
pubmed: 28290490
Ann Oncol. 2019 Mar 1;30(3):397-404
pubmed: 30475950
J Clin Oncol. 2019 Mar 1;37(7):559-569
pubmed: 30650045
J Natl Cancer Inst. 2020 Jul 1;112(7):708-719
pubmed: 31665482
Hum Pathol. 2015 Feb;46(2):182-90
pubmed: 25522926
Cell. 2018 Sep 6;174(6):1373-1387.e19
pubmed: 30193111
Ann Oncol. 2018 Apr 1;29(4):1056-1062
pubmed: 29145561
J Clin Oncol. 2019 Sep 10;37(26):2338-2348
pubmed: 31339827
Lancet. 2015 May 9;385(9980):1863-72
pubmed: 25740286
Lancet. 2017 Jun 17;389(10087):2430-2442
pubmed: 27939063
Int J Cancer. 2020 Jan 1;146(1):262-271
pubmed: 31162838
N Engl J Med. 2018 Nov 29;379(22):2108-2121
pubmed: 30345906
Ann Oncol. 2018 Jul 1;29(7):1497-1508
pubmed: 29873695
J Clin Invest. 2017 Aug 1;127(8):2930-2940
pubmed: 28650338
J Clin Invest. 2019 Apr 1;129(4):1785-1800
pubmed: 30753167
Cancer Cell. 2019 Mar 18;35(3):428-440.e5
pubmed: 30853353
Lancet Oncol. 2018 Apr;19(4):497-509
pubmed: 29501363
J Clin Oncol. 2020 Jan 20;38(3):203-213
pubmed: 31804894
Cancers (Basel). 2020 Mar 29;12(4):
pubmed: 32235297
Sci Rep. 2019 Feb 7;9(1):1538
pubmed: 30733547
J Chemother. 2016 Jun;28(3):210-7
pubmed: 26239282
Nature. 2012 Oct 4;490(7418):61-70
pubmed: 23000897
PLoS One. 2016 Jun 16;11(6):e0157368
pubmed: 27310713
Clin Cancer Res. 2015 Apr 1;21(7):1688-98
pubmed: 25208879
Nature. 2000 Aug 17;406(6797):747-52
pubmed: 10963602
Clin Cancer Res. 2019 Jul 15;25(14):4363-4374
pubmed: 30914433
Nat Med. 2018 May;24(5):628-637
pubmed: 29713086
J Natl Cancer Inst. 2016 Oct 5;109(1):
pubmed: 27707838
Ann Oncol. 2019 Oct 1;30(10):1541-1557
pubmed: 31373601
Immunity. 2020 Jan 14;52(1):17-35
pubmed: 31940268
Ann Oncol. 2020 May;31(5):569-581
pubmed: 32278621
Mutat Res. 2018 Jul - Sep;777:1-18
pubmed: 30115427
Lancet Oncol. 2014 Jun;15(7):747-56
pubmed: 24794243
Ann Oncol. 2018 Apr 1;29(4):895-902
pubmed: 29365031
Lancet Oncol. 2018 Jan;19(1):40-50
pubmed: 29233559
Target Oncol. 2020 Aug;15(4):415-428
pubmed: 32514907
Front Oncol. 2019 Jun 06;9:452
pubmed: 31245286
Ann Oncol. 2019 Aug 1;30(8):1279-1288
pubmed: 31095287
Sci Transl Med. 2017 Jun 7;9(393):
pubmed: 28592566
Lancet. 2014 Jul 12;384(9938):164-72
pubmed: 24529560
Ann Oncol. 2019 Dec 1;30(12):1941-1949
pubmed: 31566659
J Clin Oncol. 2017 Apr 1;35(10):1049-1060
pubmed: 28135148
N Engl J Med. 2017 Jun 1;376(22):2147-2159
pubmed: 28564564
PLoS One. 2019 Apr 12;14(4):e0215052
pubmed: 30978228
N Engl J Med. 2020 Feb 27;382(9):810-821
pubmed: 32101663
JAMA Oncol. 2019 Jan 1;5(1):74-82
pubmed: 30242306
Ann Oncol. 2019 Mar 1;30(3):405-411
pubmed: 30475947
Ann Oncol. 2019 Feb 1;30(2):236-242
pubmed: 30590484
J Clin Invest. 2011 Jul;121(7):2750-67
pubmed: 21633166
Nat Rev Drug Discov. 2019 Mar;18(3):175-196
pubmed: 30622344
BMJ. 2003 Sep 6;327(7414):557-60
pubmed: 12958120